COMPETING INTERESTST
F.P. reports having received research grant from AstraZeneca, Novo
Nordisk, Novartis and lecture fees from MSD, AstraZeneca, Novo Nordisk,
Novartis, Eli Lilly and Boehringer Ingelheim and have served as a
consultant for AstraZeneca, Novo Nordisk, Amgen, and MSD.
A.P. reports participation in research projects funded by Alcon,
Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk,
Servier and LEO Pharma, all with funds paid to the institution where he
was employed (no personal fees) and with no relation to the work
reported in this paper.